Newron Pharmaceuticals - Positive top-line data to support clinical progress
Newron Pharmaceuticals has announced positive top-line results from its Phase II trial (study 014) assessing evenamide, a glutamate modulator, as...
193 Views
Newron Pharmaceuticals - A year ahead of clinical milestones for evenamide
Newron has released its annual report and provided an operational overview for evenamide as a potential schizophrenia therapy. Positive interim...
214 Views
Newron Pharmaceuticals - Evenamide efficacy still going strong after 52 weeks
Newron Pharmaceuticals has announced positive interim results from the first 100 randomised patients completing one year of treatment (77 out of...
288 Views
Newron Pharmaceuticals - Positive interim trial results in schizophrenia
Newron Pharmaceuticals’ share price has responded well to its announcement of encouraging interim efficacy data for the use of evenamide as an...
675 Views
Newron Pharmaceuticals - Evenamide catalyst approaching
Newron Pharmaceuticals is focused on the development of novel compounds for the treatment of various neurological conditions. Heading the R&D...
671 Views